News & Events
Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline
Company welcomes Dr. Hua Yang, PhD, as VP, Nonclinical Development and Clinical Pharmacology and Sarah Tuller, JD as VP, Regulatory Affairs
CAMBRIDGE, Mass. (August 23, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today announced the promotions of Will Savage, MD, PhD to Chief Medical Officer and Jonathan Yu to Chief Business Officer. In addition, the company has expanded its scientific leadership with the appointments of industry veterans Hua Yang, PhD, as Vice President of Nonclinical Development and Clinical Pharmacology and Sarah Tuller, JD as Vice President of Regulatory Affairs.
“We are entering an exciting chapter of the Disc story and I’m delighted that we’ve attracted a team whose leadership and depth of experience will enable us to build a company that will make a difference in patients’ lives,“ said John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine. “I want to congratulate Will and Jonathan on their respective promotions and welcome both Hua and Sarah to the company. I’m thrilled to work with this team as we advance our clinical-stage pipeline deep into development.”
Dr. Hua Yang, PhD is the Vice President of Nonclinical Development and Clinical Pharmacology and brings over 20 years of experience in drug discovery, nonclinical development and clinical pharmacology. Prior to Disc, she served as the Vice President of DMPK and Clinical Pharmacology at Agios Pharmaceuticals, where she established these functions and was instrumental in the discovery, development, and successful approvals of its flagship programs IDHIFA® (enasidinib) in relapsed or refractory AML and TIBSOVO® (ivosidenib) in AML patients with IDH1 mutations, as well as mitapivat (PKR activator) and vorasidenib (dual IDH1/2 inhibitor). Prior to Agios, Hua held positions in DMPK and drug discovery at Millennium/Takeda Pharmaceuticals and Bristol-Myers Squibb. Hua received her BA in Pharmacology from Fudan University, an MS in Pharmacology from Peking Union Medical School and her Ph.D. in Pharmacokinetics from University of Nebraska Medical Center. She is a co-inventor on over 50 patent applications.
Sarah Tuller, JD, RAC is the Vice President of Regulatory Affairs and brings 20 years of experience in regulatory strategy and operations, spanning numerous clinical and commercial-stage products across a wide range of therapeutic indications, including multiple orphan disease programs. She has led or been a part of numerous successful IND, NDA, MAA and BLA and other submissions, including those of Portrazza® (necitumumab) in metastatic, squamous, NSCLC, Phoslyra® (calcium acetate) in ESRD, and Avonex Pen® (interferon beta-1a) in relapsing MS. Prior to joining Disc, she held leadership positions in regulatory affairs for rare disease programs at Astellas Pharma, and prior to Astellas, at companies including Biogen, Fresenius and Baxter. Sarah holds a JD from the University of Dayton School of Law and a BS in Chemistry.
Disc recently announced the initiation of a phase 1 clinical study of DISC-0974, a first-in-class inhibitor of hemojuvelin (HJV) designed to suppress hepcidin and is being developed to treat multiple forms of anemia of inflammation. The company is planning to initiate clinical studies of a separate program in early 2022 for bitopertin, a first-in-class GlyT1 inhibitor that is being developed to treat erythropoietic porphyrias, a family of severe, genetically-driven and rare hematologic disorders.
###
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates based on fundamental pathways of red blood cell biology. Disc Medicine is committed to building a brighter future for patients who suffer from hematologic disease, ranging from severe orphan conditions to widely prevalent diseases. For more information, please visit www.discmedicine.com.
Media Contact
Sarah Ellinwood, Ph.D.
Verge Scientific Communications
sellinwood@vergescientific.com
More News
Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
WATERTOWN, Mass. (December 13, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments...
read more
Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. (November 3, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments...
read more
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)
WATERTOWN, Mass. (October 31, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments...
read more
Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
WATERTOWN, Mass. (August 10, 2022) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic candidates...
read more
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
WAYLAND, Mass. and WATERTOWN, Mass. (August 10, 2022) – Gemini Therapeutics, Inc. (Nasdaq: GMTX) (“Gemini”) and Disc Medicine, Inc. (“Disc”), a privately-held,...
read more
Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia
CAMBRIDGE, Mass. (June 23, 2022) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic candidates...
read more
Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress
WATERTOWN, Mass. (June 10, 2022) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress
WATERTOWN, Mass. (May 16, 2022) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel
CAMBRIDGE, Mass. (January 4, 2022) - Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for...
read more
Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. (November 11, 2021) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for...
read more
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
CAMBRIDGE, Mass. (September 2, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for...
read more
Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation
CAMBRIDGE, Mass. (July 28, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapies for the...
read more
Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis
CAMBRIDGE, Mass. (May 27, 2021) – Disc Medicine, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with...
read more
Disc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress
CAMBRIDGE, Mass. (May 24, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious...
read more
Disc Medicine Appoints William White to its Board of Directors
CAMBRIDGE, Mass. (January 13th, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference
CAMBRIDGE, Mass. (November 23, 2020) – Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine Expands Scientific Advisory Board with Leading Experts in Hepcidin Biology
Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to Join Disc Medicine Scientific Advisory Board Cambridge, Mass. – October 13, 2020 –...
read more
Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference
Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates...
read more
Disc Medicine Expands Leadership Team with Industry Veterans to Advance Hepcidin Modulating Therapies Toward the Clinic
Jonathan Yu Named Senior Vice President of Corporate Strategy William Savage, MD, PhD Appointed Vice President of Clinical Development
read more
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that...
read more
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic...
read more
Disc Medicine Expands Pipeline Focused on Hepcidin Pathway
Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicine,...
read more
Introducing Disc Medicine, a New Hematology Company
Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions...
read more